Almirall

Life Science/Pharmaceutical Industry/Pharmaceutical Research Industry

Barcelona, Spain

Description

Almirall, founded in 1944, is a publicly traded pharmaceutical company headquartered in Barcelona, Spain. The company employs approximately 1,900 staff and specialises in medical dermatology, with a focus on innovative treatments for skin conditions. Its operations serve both B2B and B2C customer segments across the globe. Almirall reported a turnover of €898.8 million, reflecting its substantial global presence. The company's business model centres on the development, manufacturing, and commercialisation of dermatological medicines, catering to a wide range of skin-related health issues. With a significant footprint in the pharmaceutical sector, Almirall maintains a main office in Barcelona and operates through various subsidiaries worldwide.

Experteer Insights

Locations 3

Experteer Briefing

Company Trajectory

Founded in 1944 in Barcelona, Spain, Almirall has evolved from its roots in pharmaceutical development and marketing to become a prominent force in the healthcare industry. Initially, the company focused on a broad range of therapeutic areas, but over time Almirall has strategically refined its focus, expanding into new markets and establishing itself as a key player in medical dermatology. The company's main headquarters remain in Barcelona, reflecting its strong Spanish heritage. Almirall’s evolution has included strategic pivots and growth through market expansions, positioning the company for continued leadership in specialised pharmaceutical solutions.

Financial Setup

Almirall is a publicly traded enterprise, serving both B2B and B2C markets with a workforce of approximately 1,900 employees. The company’s financial configuration reflects its solid footing in the industry, underpinned by its commitment to innovation and long-term value creation. Its publicly traded status provides transparency and access to capital markets, supporting ongoing investments in research and commercial operations. This structure enables Almirall to pursue advanced development initiatives while maintaining strong relationships with stakeholders across the pharmaceutical value chain.

Development & Outlook

Almirall’s current focus is medical dermatology, with a portfolio of innovative products including Ebglyss, Ilumetri, Wynzora, Klisyri, Seysara, Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, and Actikerall. The company actively develops and launches proprietary treatments, underscoring its strong commitment to research and intellectual property protection. Almirall’s sustainability strategy aligns with the United Nations Sustainable Development Goals (SDGs), exemplifying its proactive stance on environmental, social responsibility, diversity, equity, inclusion, and regulatory compliance. This integrated approach ensures Almirall’s activities generate positive impact for patients and the broader society, with a future vision centred on innovative healthcare solutions and responsible business practices.